Pfizer execs say there’s a ‘significant opportunity’ to hike prices of its COVID vaccine
Execs told the company’s investors that people may also need a third dose of the COVID vaccine, as well as regular yearly boosters.
Pfizer execs told investors there was a “significant opportunity” to hike the price of its vaccine.
They said to cope with emerging COVID variants, people may need a third dose of the vaccine.
Regular yearly “booster jabs” against COVID may also become routine.
Pfizer execs have informed the company’s investors of a “significant opportunity” to hike the prices of the Pfizer-BioNTech vaccine.
Speaking at the virtual Barclays Global Healthcare Conference last week, two high-ranking Pfizer employees – CFO Frank D’Amelio and Chuck Triano, senior VP of investor relations – said there would be a chance for Pfizer to raise prices for the vaccine when COVID moves from a pandemic state to an endemic situation and the virus circulates continually in pockets around the globe.
“If you look at how current demand and current pricing is being driven, it’s clearly not being driven by what I’ll call normal market conditions or normal market forces… it’s been driven by the pandemic state we’ve been in, and the needs of governments to secure doses from various vaccine suppliers,” said D’Amelio.
